Vaccinex, Inc. (VCNX)
NASDAQ: VCNX · Real-Time Price · USD
4.195
+0.065 (1.57%)
Dec 3, 2024, 11:42 AM EST - Market open
Vaccinex Employees
As of December 31, 2023, Vaccinex had 40 total employees, including 37 full-time and 3 part-time employees. The number of employees decreased by 3 or -6.98% compared to the previous year.
Employees
40
Change (1Y)
-3
Growth (1Y)
-6.98%
Revenue / Employee
$9,700
Profits / Employee
-$464,425
Market Cap
10.91M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Trinity Biotech | 380 |
Evogene | 142 |
ImmunoPrecise Antibodies | 101 |
Aptose Biosciences | 36 |
Dominari Holdings | 28 |
SeaStar Medical Holding | 12 |
Ensysce Biosciences | 7 |
VCNX News
- 15 days ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 26 days ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 4 weeks ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire
- 4 weeks ago - Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain - GlobeNewsWire
- 2 months ago - Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds - GlobeNewsWire
- 3 months ago - Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership - GlobeNewsWire
- 4 months ago - Vaccinex stock tanks 40% despite positive Alzheimer's study update - Invezz
- 6 months ago - Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease - GlobeNewsWire